EA202190360A1 - Комбинированная терапия - Google Patents

Комбинированная терапия

Info

Publication number
EA202190360A1
EA202190360A1 EA202190360A EA202190360A EA202190360A1 EA 202190360 A1 EA202190360 A1 EA 202190360A1 EA 202190360 A EA202190360 A EA 202190360A EA 202190360 A EA202190360 A EA 202190360A EA 202190360 A1 EA202190360 A1 EA 202190360A1
Authority
EA
Eurasian Patent Office
Prior art keywords
combination therapy
inhibitor
effective amount
kinase
methods
Prior art date
Application number
EA202190360A
Other languages
English (en)
Russian (ru)
Inventor
Дэниел П. Голд
Original Assignee
Мей Фарма, Инк
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Мей Фарма, Инк filed Critical Мей Фарма, Инк
Publication of EA202190360A1 publication Critical patent/EA202190360A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EA202190360A 2018-08-14 2019-08-13 Комбинированная терапия EA202190360A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862718925P 2018-08-14 2018-08-14
PCT/US2019/046405 WO2020036995A1 (en) 2018-08-14 2019-08-13 Combination therapy

Publications (1)

Publication Number Publication Date
EA202190360A1 true EA202190360A1 (ru) 2021-07-15

Family

ID=69525833

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202190360A EA202190360A1 (ru) 2018-08-14 2019-08-13 Комбинированная терапия

Country Status (9)

Country Link
US (1) US20210161909A1 (https=)
JP (1) JP2021534114A (https=)
CN (1) CN112839651A (https=)
AU (1) AU2019322858A1 (https=)
EA (1) EA202190360A1 (https=)
IL (1) IL280729A (https=)
MX (1) MX2021001764A (https=)
TW (1) TW202021592A (https=)
WO (1) WO2020036995A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11304953B2 (en) 2017-05-23 2022-04-19 Mei Pharma, Inc. Combination therapy
AU2023228576A1 (en) * 2022-03-01 2024-09-26 Mei Pharma, Inc. Combination therapy of pi3k inhibitor and pd-1 inhibitor
CN118949002A (zh) * 2024-10-15 2024-11-15 杭州阿克索生物科技有限责任公司 一种宫颈癌细胞抑制组合物及其制备方法和应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8563596B2 (en) * 2006-06-21 2013-10-22 Piramal Enterprises Limited Enantiomerically pure compounds for the treatment of proliferative disorders
ES2608967T3 (es) * 2011-03-28 2017-04-17 Mei Pharma, Inc. (Aralquilamino sustituido en alfa y heteroarilalquilamino)pirimidinil y 1,3,5-triazinil benzimidazoles, composiciones farmacéuticas que los contienen, y estos compuestos para usar en el tratamiento de enfermedades proliferativas
WO2014055647A1 (en) * 2012-10-03 2014-04-10 Mei Pharma, Inc. (sulfinyl and sulfonyl benzimidazolyl) pyrimidines and triazines, pharmaceutical compositions thereof, and their use for treating proliferative diseases
TW201618773A (zh) * 2014-08-11 2016-06-01 艾森塔製藥公司 Ｂｔｋ抑制劑、ｐｉ３ｋ抑制劑、ｊａｋ－２抑制劑、及／或ｃｄｋ４／６抑制劑的治療組合物
RU2726367C2 (ru) * 2016-03-28 2020-07-13 Пресидж Байосайенсиз, Инк. Фармацевтические комбинации для лечения злокачественной опухоли
CN109982687A (zh) * 2016-09-19 2019-07-05 梅制药公司 联合疗法
US11304953B2 (en) * 2017-05-23 2022-04-19 Mei Pharma, Inc. Combination therapy
KR20200041358A (ko) * 2017-08-14 2020-04-21 메이 파마, 아이엔씨. 병용 요법

Also Published As

Publication number Publication date
MX2021001764A (es) 2021-04-19
IL280729A (en) 2021-03-25
WO2020036995A1 (en) 2020-02-20
CN112839651A (zh) 2021-05-25
US20210161909A1 (en) 2021-06-03
AU2019322858A1 (en) 2021-04-01
JP2021534114A (ja) 2021-12-09
TW202021592A (zh) 2020-06-16

Similar Documents

Publication Publication Date Title
EA202092154A1 (ru) Комбинированная терапия
MX2020004023A (es) Uso de un inhibidor de pcsk9 para tratar la hiperlipidemia.
MX391720B (es) Terapia combinada para tratar cáncer.
EA201890146A1 (ru) СПОСОБЫ ЛЕЧЕНИЯ СОЛИДНЫХ ОПУХОЛЕЙ С ИСПОЛЬЗОВАНИЕМ КОМБИНИРОВАННОЙ ТЕРАПИИ ИНГИБИТОРОМ mTOR В ВИДЕ НАНОЧАСТИЦ
BR112015026297A2 (pt) terapia combinada composta por um inibidor tor quinase e um composto de 5-quinazolinona substituído para o tratamento de câncer
JO3589B1 (ar) مثبطات كيناز البروتين c وطرق استخداماتها
EA201892075A1 (ru) Комбинации ингибиторов lsd1 для применения для лечения солидных опухолей
BR112015026247A2 (pt) métodos para o tratamento de câncer com o uso de terapia combinada com inibidor de cinase tor
MX2017000628A (es) Metodos para tratar pacientes de alto riesgo cardiovascular con hipercolesterolemia.
MX390121B (es) Combinaciones de un inhibidor de btk y un inhibidor de pi3k para tratar neoplasias malignas hematológicas.
MX373231B (es) Agente anticancerigeno.
MX2020001727A (es) Terapia de combinacion.
CL2020000270A1 (es) Combinación terapéutica de un inhibidor tirosina quinasa del egfr de tercera generación y un inhibidor raf.
MX2019013862A (es) Terapia de combinacion.
CL2021003032A1 (es) Métodos de tratamiento de la urticaria crónica espontánea utilizando un inhibidor de la tirosina quinasa de bruton
MX2021014161A (es) Metodos de tratamiento del sindrome de sjogren utilizando un inhibidor de la tirosina quinasa de bruton.
MX2023004156A (es) Terapia combinada para el tratamiento del cancer.
EA202191165A1 (ru) Элацестрант в комбинации с абемациклибом у женщин с раком молочной железы
EA202190360A1 (ru) Комбинированная терапия
EA202190457A1 (ru) Конъюгаты для применения в способах лечения рака
MX2021007330A (es) Composiciones y métodos terapéuticos para tratar cáncer usando ácido 6, 8-bis-benciltio-octanoico y un inhibidor de autofagia.
PH12021551276A1 (en) Combination therapy for the treatment of cancer
EA202192964A1 (ru) Комбинированная терапия
MX2021003160A (es) Combinaciones de inhibidores de tgfbeta e inhibidores de cdk para el tratamiento de cancer de mama.
MX393477B (es) Combinación de vorasidenib con radiación y/o agentes adicionales para tratar gliomas.